George Eric Davis Sells 1,850 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 1,850 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $85.01, for a total transaction of $157,268.50. Following the completion of the sale, the executive vice president now owns 56,157 shares of the company’s stock, valued at approximately $4,773,906.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

George Eric Davis also recently made the following trade(s):

• On Thursday, March 28th, George Eric Davis sold 24,602 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $88.34, for a total transaction of $2,173,340.68.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $82.58 on Wednesday. The stock has a market cap of $15.68 billion, a price-to-earnings ratio of 77.18, a P/E/G ratio of 1.30 and a beta of 0.34. The company has a quick ratio of 1.70, a current ratio of 2.74 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical Inc. has a twelve month low of $76.02 and a twelve month high of $99.56. The company’s fifty day moving average is $86.56 and its 200 day moving average is $89.02.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. BioMarin Pharmaceutical had a return on equity of 5.34% and a net margin of 8.31%. The company had revenue of $646.21 million during the quarter, compared to the consensus estimate of $639.53 million. During the same period last year, the company earned $0.11 earnings per share. The firm’s revenue was up 20.2% compared to the same quarter last year. Sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 1.98 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on BMRN shares. Wells Fargo & Company lifted their price objective on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, April 25th. Citigroup reduced their price objective on shares of BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. Robert W. Baird reduced their price target on shares of BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 30th. Canaccord Genuity Group cut their target price on BioMarin Pharmaceutical from $91.00 to $89.00 and set a “hold” rating for the company in a research note on Friday, April 26th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $100.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.50.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently modified their holdings of BMRN. Headlands Technologies LLC lifted its holdings in BioMarin Pharmaceutical by 344.3% in the first quarter. Headlands Technologies LLC now owns 5,692 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 4,411 shares during the period. Comgest Global Investors S.A.S. raised its position in shares of BioMarin Pharmaceutical by 6.6% in the 1st quarter. Comgest Global Investors S.A.S. now owns 212,464 shares of the biotechnology company’s stock worth $18,557,000 after acquiring an additional 13,143 shares in the last quarter. Forsta AP Fonden boosted its position in shares of BioMarin Pharmaceutical by 12.4% during the 1st quarter. Forsta AP Fonden now owns 36,300 shares of the biotechnology company’s stock valued at $3,170,000 after purchasing an additional 4,000 shares in the last quarter. Oppenheimer & Co. Inc. grew its stake in BioMarin Pharmaceutical by 70.5% during the first quarter. Oppenheimer & Co. Inc. now owns 4,714 shares of the biotechnology company’s stock worth $412,000 after purchasing an additional 1,949 shares during the period. Finally, Mesirow Institutional Investment Management Inc. lifted its stake in BioMarin Pharmaceutical by 8.5% in the first quarter. Mesirow Institutional Investment Management Inc. now owns 31,760 shares of the biotechnology company’s stock valued at $2,774,000 after buying an additional 2,499 shares during the period. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.